Franco Lori, MD, President and CEO, ViroStatics, Aleghero, Italy
Dr. Lori describes his work and overviews other work at the CROI on immune hyperactivation that remains even when the viral load is controlled by the anti-HIV treatments. He describes the Virostatic compound’s ability to quickly reduce immune overactivation, and where they are with establishing dose levels and the next steps for this approach at ViroStatics and with future partners.
To download an audio mp3 file, right-click here and choose “Save”.